Ophthalmology Research

 

The Houston Methodist Blanton Eye Institute is looking ahead to the future, investing time and resources in both research and technology. We are innovating in clinical care for the following important eye diseases and procedures:

- Ocular oncology
- Diabetic retinopathy
- Thyroid ophthalmopathy
- Ocular infectious
- Ocular inflammatory diseases
- Ocular stem cell and gene therapies
- Neuroprotection in neuroophthalmology and glaucoma

 

At Houston Methodist, we invest in bringing new technology to our patients. By providing the best, most up-to-date equipment and services, we are better able to help the patients who seek treatment for some of the most challenging and complex cases. This is why Houston Methodist offers state-of-the-art neuroimaging technology in the form of a 3 Tesla (3T) magnetic resonance image (MRI) magnet and 64-slice computed tomography (CT) scanner, as well as treatment options, such as stereotactic conformal radiotherapy, image-guided therapies, TomoTherapy® and linear accelerator technology.

By stewarding technological breakthroughs and using the technology we already have at hand to the best advantage, we are confident that we can realize our goal: taking care of the eyes of tomorrow through our hard work today. Join our team as a colleague or a collaborator and become a part of the next generation of innovators in ophthalmology.

3

Active Clinical Trials

22

Academic Partners

166

Peer-Reviewed Publications in 2023
Recent News
DMO Patients Show Improved Outcomes With Increased Dose of Aflibercept in Phase 2/3 Trial
Intravitreal Aflibercept 8 mg vs. 2 mg demonstrated efficacy and safety with extended dosing intervals and could decrease treatment burden in patients with diabetic macular oedema.
Dynamic Visual Acuity, Vestibulo-Ocular Reflex, and Visual Field in National Football League (NFL) Officiating
Physiology and Visualization Engineering for 3D Virtual On-Field Training: A review of the current and past research in this space regarding a neuro-ophthalmic curriculum for NFL officials.
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314
The primary outcome of this phase 1/2a dose escalation study was safety of RGX-314 delivered by subretinal injection in patients with neovascular age-related macular degeneration for up to week 26.
Spaceflight Associated Neuro-Ocular Syndrome
Dr. Andrew Lee contributed to this paper exploring the proposed pathogenesis, terrestrial analogues and emerging countermeasures for SANS.

Explore the following:

Donate to Houston Methodist

With your support, Houston Methodist provides exceptional research, education, and care that is truly leading medicine.

Donate Now